Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)

The National Cancer Institute (NCI) is seeking applications for Exploratory/Developmental Bioengineering Research Grants (EBRG) to demonstrate the feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility. * The grant is available for a wide range of applicant types, including special district governments, small businesses, public housing authorities, Native American tribal governments, and non-profits. * The grant is intended to support exploratory/developmental research, with a focus on bioengineering approaches. * The grant will be awarded for a period of up to 2 years, with a maximum budget of $275,000 in direct costs per year. * Applications are due by January 7, 2028.